TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007
July 23 2018 - 4:00PM
REGULATED
INFORMATION
PRESS RELEASE
Transparency
notification
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium)
- July 23, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and
Nasdaq: TIG; "TiGenix") announced today that it received a
transparency notification pursuant to Article 14 of the Belgian Law
of May 2, 2007 regarding the publication of major holdings in
issuers whose securities are admitted to trading on a regulated
market and including various provisions.
Summary of the
notification
On July 18, 2018, TiGenix received
a transparency notification from Takeda Pharmaceutical Company
Limited following the acquisition of voting securities or voting
rights on July 10, 2018, after which Takeda Pharmaceutical Company
Limited (including through its subsidiary Takeda Pharmaceuticals
International AG) holds 295,908,082 voting rights in TiGenix
(96.08% of the total number of voting rights). As a result Takeda
Pharmaceutical Company Limited crossed the 95% threshold of the
total voting rights of TiGenix.
Content of the
notification
Date of the
notification: July 17, 2018.
Reason of the
notification: acquisition or disposal of voting securities or
voting rights.
Persons subject
to the notification requirement: Takeda Pharmaceutical Company
Limited (with address at 1-1 Doshomachi 4-Chome, Chuo-ku, Osaka
540-8645, Japan), who is a parent undertaking/controlling
person.
Date on which the
threshold was crossed: July 10, 2018.
Threshold that
was crossed: 95%.
Denominator:
307,973,027.
Details of the
notification: following the acquisition of voting securities or
voting rights, the number of voting rights was as follows:
-
Takeda Pharmaceutical Company Limited held
284,256,304 voting securities (92.30% of the total number of voting
rights); and
-
Takeda Pharmaceuticals International AG held
11,651,778 voting securities (3.78% of the total number of voting
rights);
Total: 295,908,082 voting rights (96.08% of the
total number of voting rights).
Chain of
controlled undertakings through which the holdings are effectively
held: Takeda Pharmaceuticals International AG is controlled by
Takeda Pharma A/S, which is controlled by Takeda A/S, which is
controlled by Takeda Pharmaceutical Company Limited and by Takeda
Europe Holdings B.V., which is controlled by Takeda Pharmaceutical
Company Limited. Takeda Pharmaceutical Company Limited is not a
controlled entity.
This press release and the above-mentioned
transparency notification can be consulted on our website:
For more
information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV
(Euronext Brussels and NASDAQ: TIG) is an advanced
biopharmaceutical company developing novel therapies for serious
medical conditions by exploiting the anti-inflammatory properties
of allogeneic, or donor-derived, stem cells.
TiGenix lead
product, Alofisel (darvadstrocel), previously Cx601, received
European Commission (EC) approval for the treatment of complex
perianal fistulas in adult patients with non-active/mildly active
luminal Crohn's disease, when fistulas have shown an inadequate
response to at least one conventional or biologic therapy. A global
Phase III trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: TiGenix via Globenewswire
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024